Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners
Innate Pharma (NASDAQ:IPHA – Get Free Report)‘s stock had its “market perform” rating restated by stock analysts at Leerink Partners in a report released on Thursday, Marketbeat reports. They presently have a $2.00 target price on the stock, down from their p…